查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1598430

溶栓藥物市場：按類型、類別和分銷管道分類 - 全球預測 2025-2030

Thrombolytic Drug Market by Types (Fibrin Specific Drugs, Nonfibrin-Specific Drugs), Category (Abbokinase, Eminase, RETAVASE), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年溶栓藥物市場價值為12.2億美元，預計2024年將達到14.3億美元，複合年成長率為17.74%，到2030年將達到38.3億美元。

溶栓劑（溶栓劑）溶解血管中危險的血栓，改善血流並防止組織和器官損傷。需求主要在於其在治療急性心肌梗塞、缺血性中風和肺動脈栓塞方面具有挽救生命的潛力。這項重要的醫療應用也擴展到醫院、診所和急救服務，在這些地方，快速清除血栓至關重要。根據市場洞察，心血管疾病的增加和醫療基礎設施的進步正在推動這一成長。此外，配方技術的改進提高了功效和安全性，從而導致更廣泛的採用。然而，市場面臨挑戰，包括高昂的治療成本、潛在的副作用以及需要熟練的專業人員安全有效地管理這些藥物。如果沒有可靠的報銷結構或明確的成本效益證據，醫院和醫療保健系統可能不願意投資昂貴的治療，這可能成為市場擴張的主要障礙。

主要市場統計
基準年[2023] 12.2億美元
預測年份 [2024] 14.3億美元
預測年份 [2030] 38.3億美元
複合年成長率（%） 17.74%

開發更具針對性的溶栓劑、副作用更少和起效更快的製劑，可以更有效地緩解危急情況，具有很大的潛力。透過奈米技術等創新的給藥方法以及探索這些藥物治療其他閉塞性和血管疾病的用途，還有擴大應用的潛力。專注於改進給藥技術（例如最大限度地減少副作用和簡化給藥計劃）的研究的公司將獲得競爭優勢。同時，與公共衛生機構合作以提高及時溶栓干預的意識可能會刺激市場需求。儘管受到嚴格法規和競爭格局的限制，但競爭格局可以利用新技術來應對當前挑戰並探索重大創新。總體而言，市場擴張強勁，但解決系統性醫療保健障礙並專注於研究創新對於未來的成長和永續性至關重要。

市場動態：揭示快速發展的溶栓市場的關鍵市場洞察

供需的動態交互作用正在改變溶栓藥物市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 提高患者對纖溶治療的認知
    • 腎臟疾病、中風和高血壓的盛行率飆升
    • 有利的藥品報銷方案
  • 市場限制因素
    • 藥物和治療費用上漲
  • 市場機會
    • 治療技術的進步和零售藥局的增加
    • 增加醫療支出和增加協作活動
  • 市場挑戰
    • 嚴格的藥品監管體系

波特五力：駕馭溶栓藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解溶栓藥物市場的外部影響

外部宏觀環境因素在塑造溶栓藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解溶栓藥物市場的競爭格局

對溶栓藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣溶栓藥物市場供應商績效評估

FPNV 定位矩陣是評估溶栓藥物市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，以規劃溶栓藥物市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，溶栓藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 提高患者對纖溶治療的認知
      • 腎臟疾病、中風和高血壓的發生率飆升
      • 有利的藥品報銷方案
    • 抑制因素
      • 藥物和治療費用高昂
    • 機會
      • 治療技術進步與零售藥局的興起
      • 醫療費用增加和關節活動增加
    • 任務
      • 嚴格的藥品管制制度
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章溶栓藥物市場：依類型

  • 纖維蛋白特異性藥物
  • 非纖維蛋白特異性藥物

第7章溶栓藥物市場：依類別

  • 阿沃激酶
  • 埃米納酶
  • 麗塔貝斯
  • 鏈黴酶
  • TNK酶

第8章溶栓藥物市場：按分銷管道

  • 網路藥局
  • 醫院藥房
  • 零售藥房

第9章美洲溶栓市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太溶栓藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲溶栓藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AstraZeneca PLC
  • Becton, Dickinson and Company（BD）
  • Boehringer Ingelheim International GmbH
  • Boston Scientific Corporation
  • Chiesi Farmaceutici SPA
  • Eli Lilly and Company
  • Medtronic PLC
  • Microbix Biosystems, Inc.
  • Pfizer, Inc.
  • Sanofi SA
  • Siemens Healthineers AG
  • Sigma-Aldrich Corporation
  • Synergy Medical Inc
  • Taj Pharmaceuticals Ltd.
  • Teleflex Incorporated
Product Code: MRR-43286DA07EA6

The Thrombolytic Drug Market was valued at USD 1.22 billion in 2023, expected to reach USD 1.43 billion in 2024, and is projected to grow at a CAGR of 17.74%, to USD 3.83 billion by 2030.

Thrombolytic drugs, or clot busters, dissolve dangerous clots in blood vessels, improving blood flow and preventing damage to tissues and organs. Their necessity lies in their life-saving potential, primarily in treating acute myocardial infarction, ischemic stroke, and pulmonary embolism. This critical medical application extends to hospitals, clinics, and emergency services where rapid clot resolution is imperative. Market insights reveal growth driven by increasing incidences of cardiovascular diseases and advancements in healthcare infrastructure. Additionally, technological improvements in drug formulation enhance efficacy and safety profiles, encouraging broader adoption. However, the market faces challenges, including high therapy costs, potential side effects, and the requirement for skilled professionals to administer these drugs safely and efficiently. Hospitals and healthcare systems may be reluctant to invest in expensive treatments without solid reimbursement structures or clear evidence of cost-effectiveness, which can be a significant hurdle in market expansion.

KEY MARKET STATISTICS
Base Year [2023] USD 1.22 billion
Estimated Year [2024] USD 1.43 billion
Forecast Year [2030] USD 3.83 billion
CAGR (%) 17.74%

Opportunities abound in the development of more targeted thrombolytic agents with fewer side effects or rapid-acting formulations that could alleviate time-critical conditions more effectively. There is also potential in expanding applications through innovative delivery methods such as nanotechnology or exploring these drugs' use in combating other blockages or vascular diseases. Companies focusing on research to minimize adverse reactions and improve administration techniques, such as easier dosing schedules, could gain a competitive edge. Meanwhile, partnerships with public health entities to raise awareness about timely thrombolytic intervention might stimulate market demand. Although limited by stringent regulations and competitive landscapes, the thrombolytic drug market can explore significant innovation by addressing present challenges and harnessing emerging technologies. Overall, while market expansion is robust, addressing systemic healthcare barriers and emphasizing research innovations are vital for future growth and sustainability.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Thrombolytic Drug Market

The Thrombolytic Drug Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing patient awareness regarding fibrinolytic therapy
    • Surge in prevalence of kidney diseases, stroke, and hypertension
    • Favorable reimbursement scenario for the drugs
  • Market Restraints
    • High cost of the medicines and treatment
  • Market Opportunities
    • Technological advancements in the treatment and increasing number of retail pharmacies
    • Growing healthcare expenditure and rise of collaborative activities
  • Market Challenges
    • Strict drug regulatory systems

Porter's Five Forces: A Strategic Tool for Navigating the Thrombolytic Drug Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Thrombolytic Drug Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Thrombolytic Drug Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Thrombolytic Drug Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Thrombolytic Drug Market

A detailed market share analysis in the Thrombolytic Drug Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Thrombolytic Drug Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Thrombolytic Drug Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Thrombolytic Drug Market

A strategic analysis of the Thrombolytic Drug Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Thrombolytic Drug Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Becton, Dickinson and Company (BD), Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Chiesi Farmaceutici S.P.A., Eli Lilly and Company, Medtronic PLC, Microbix Biosystems, Inc., Pfizer, Inc., Sanofi S.A., Siemens Healthineers AG, Sigma-Aldrich Corporation, Synergy Medical Inc, Taj Pharmaceuticals Ltd., and Teleflex Incorporated.

Market Segmentation & Coverage

This research report categorizes the Thrombolytic Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Types, market is studied across Fibrin Specific Drugs and Nonfibrin-Specific Drugs.
  • Based on Category, market is studied across Abbokinase, Eminase, RETAVASE, Streptase, and TNKase.
  • Based on Distribution Channel, market is studied across Electronic Pharmacy, Hospital Pharmacy, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing patient awareness regarding fibrinolytic therapy
      • 5.1.1.2. Surge in prevalence of kidney diseases, stroke, and hypertension
      • 5.1.1.3. Favorable reimbursement scenario for the drugs
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of the medicines and treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in the treatment and increasing number of retail pharmacies
      • 5.1.3.2. Growing healthcare expenditure and rise of collaborative activities
    • 5.1.4. Challenges
      • 5.1.4.1. Strict drug regulatory systems
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Thrombolytic Drug Market, by Types

  • 6.1. Introduction
  • 6.2. Fibrin Specific Drugs
  • 6.3. Nonfibrin-Specific Drugs

7. Thrombolytic Drug Market, by Category

  • 7.1. Introduction
  • 7.2. Abbokinase
  • 7.3. Eminase
  • 7.4. RETAVASE
  • 7.5. Streptase
  • 7.6. TNKase

8. Thrombolytic Drug Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Electronic Pharmacy
  • 8.3. Hospital Pharmacy
  • 8.4. Retail Pharmacies

9. Americas Thrombolytic Drug Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Thrombolytic Drug Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Thrombolytic Drug Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AstraZeneca PLC
  • 2. Becton, Dickinson and Company (BD)
  • 3. Boehringer Ingelheim International GmbH
  • 4. Boston Scientific Corporation
  • 5. Chiesi Farmaceutici S.P.A.
  • 6. Eli Lilly and Company
  • 7. Medtronic PLC
  • 8. Microbix Biosystems, Inc.
  • 9. Pfizer, Inc.
  • 10. Sanofi S.A.
  • 11. Siemens Healthineers AG
  • 12. Sigma-Aldrich Corporation
  • 13. Synergy Medical Inc
  • 14. Taj Pharmaceuticals Ltd.
  • 15. Teleflex Incorporated

LIST OF FIGURES

  • FIGURE 1. THROMBOLYTIC DRUG MARKET RESEARCH PROCESS
  • FIGURE 2. THROMBOLYTIC DRUG MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. THROMBOLYTIC DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. THROMBOLYTIC DRUG MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. THROMBOLYTIC DRUG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. THROMBOLYTIC DRUG MARKET DYNAMICS
  • TABLE 7. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY FIBRIN SPECIFIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY NONFIBRIN-SPECIFIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY ABBOKINASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY EMINASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY RETAVASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY STREPTASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY TNKASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY ELECTRONIC PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM THROMBOLYTIC DRUG MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM THROMBOLYTIC DRUG MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM THROMBOLYTIC DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. THROMBOLYTIC DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. THROMBOLYTIC DRUG MARKET, FPNV POSITIONING MATRIX, 2023